KU Leuven

Biohaven Enters Exclusive License and Research Collaboration Agreement with KU Leuven to Advance First-in-Class TRPM3 Antagonists for the Treatment of Pain

Retrieved on: 
Monday, January 10, 2022
Health, Pain, Alzheimer's disease, U.S. Securities and Exchange Commission, Annual report, Program, Partnership, Migraine, European Investment Fund, Tic disorder, FDA, Technology transfer, Pain management, TRP, Ion, Security (finance), Board, Student, Science, Center, MPO, Private Securities Litigation Reform Act, Company, Doctor of Philosophy, Drug design, Chronic pain, Analgesic, Transient receptor potential channel, Pain disorder, Amyotrophic lateral sclerosis, Drug discovery, Patient, Takeda Pharmaceutical Company, Research, Therapy, Transience, NYSE, News, Intellectual property, LICR, Disease, Risk, LRD, Industry, Spinocerebellar ataxia, CGRP, CD3, TRPM3, Pharmaceutical industry, Dentistry, HAVEN, KU Leuven, Development

TRPM3 is a cation channel involved in pain signaling and a novel target for the treatment of pain discovered at KU Leuven's LICR.

Key Points: 
  • TRPM3 is a cation channel involved in pain signaling and a novel target for the treatment of pain discovered at KU Leuven's LICR.
  • There is an urgent unmet need for safe, effective treatments for pain, and TRPM3 antagonism is a promising approach to advance new pain therapies.
  • Under the agreement, Biohaven Therapeutics receives exclusive global rights to develop, manufacture and commercialize KU Leuven's small-molecule TRPM3 antagonists.
  • Biohaven Therapeutics will support further basic and translational research at KU Leuven on the role of TRPM3 in pain and other disorders.

SkylineDx and VIB enter a strategic partnership in molecular diagnostics

Retrieved on: 
Wednesday, December 22, 2021
Physician, IVD, Disease, KU Leuven, Patient, Inflammation, CEO, Life Sciences Institute, Vrije Universiteit Brussel, University, Hasselt University, VIB, Ghent University, Research, List, Biomarker, Partnership, University of Antwerp, Medical device, Pharmaceutical industry

ROTTERDAM, Netherlands andSAN DIEGO and GHENT, Belgium, Dec. 22, 2021 /PRNewswire/ -- Today, SkylineDxannounced a 3-year strategic partnership with life sciences institute VIB for the evaluation and initiation of collaborative projects focused on molecular diagnostics.

Key Points: 
  • ROTTERDAM, Netherlands andSAN DIEGO and GHENT, Belgium, Dec. 22, 2021 /PRNewswire/ -- Today, SkylineDxannounced a 3-year strategic partnership with life sciences institute VIB for the evaluation and initiation of collaborative projects focused on molecular diagnostics.
  • Under the agreement, SkylineDx and VIB will jointly evaluate opportunities regarding novel molecular diagnostics, combining VIB's expertise in state-of-the-art single-cell analysis and biomarker discovery applied to molecular pathology and precision diagnostics with SkylineDx' strategic expertise, global network of renowned clinical centers and physicians, and know-how in the development, market access and early commercialization of in vitro diagnostics.
  • VIB has done cutting edge biotech discoveries and has an impressive start-up portfolio," comments Dharminder Chahal, CEO SkylineDx.
  • SkylineDx is a biotechnology company, focused on research & development of molecular diagnostics in oncology and inflammatory diseases.

SkylineDx and VIB enter a strategic partnership in molecular diagnostics

Retrieved on: 
Wednesday, December 22, 2021
Physician, IVD, Disease, KU Leuven, Patient, Inflammation, CEO, Life Sciences Institute, Vrije Universiteit Brussel, University, Hasselt University, VIB, Ghent University, Research, List, Biomarker, Partnership, University of Antwerp, Medical device, Pharmaceutical industry

ROTTERDAM, Netherlands andSAN DIEGO and GHENT, Belgium, Dec. 22, 2021 /PRNewswire/ -- Today, SkylineDxannounced a 3-year strategic partnership with life sciences institute VIB for the evaluation and initiation of collaborative projects focused on molecular diagnostics.

Key Points: 
  • ROTTERDAM, Netherlands andSAN DIEGO and GHENT, Belgium, Dec. 22, 2021 /PRNewswire/ -- Today, SkylineDxannounced a 3-year strategic partnership with life sciences institute VIB for the evaluation and initiation of collaborative projects focused on molecular diagnostics.
  • Under the agreement, SkylineDx and VIB will jointly evaluate opportunities regarding novel molecular diagnostics, combining VIB's expertise in state-of-the-art single-cell analysis and biomarker discovery applied to molecular pathology and precision diagnostics with SkylineDx' strategic expertise, global network of renowned clinical centers and physicians, and know-how in the development, market access and early commercialization of in vitro diagnostics.
  • VIB has done cutting edge biotech discoveries and has an impressive start-up portfolio," comments Dharminder Chahal, CEO SkylineDx.
  • SkylineDx is a biotechnology company, focused on research & development of molecular diagnostics in oncology and inflammatory diseases.

Longitudinal Study Indicates High Exhaled Viral Load Early in the Course of a SARS-CoV-2 Infection

Retrieved on: 
Tuesday, December 21, 2021
Aerosol, Flemish Government, IMEC, KU Leuven, Disease, Silicon, Christmas, Education, Viral load, Public health, Infection, UZ Leuven, Industry, ICT, Artificial intelligence, Health, PCR, Trial of the century, Severe acute respiratory syndrome coronavirus 2, Research, Multimedia, Preprint, Exhaled breath condensate, International, Saliva, Vaccine

A longitudinal study, including unprecedented molecular tests performed on aerosols, reveals that exhaled viral load (the purported measurement of contagiousness) peaks before rapid antigen tests are reliably positive.

Key Points: 
  • A longitudinal study, including unprecedented molecular tests performed on aerosols, reveals that exhaled viral load (the purported measurement of contagiousness) peaks before rapid antigen tests are reliably positive.
  • The findings imply that people can spread the virus early in the course of an infection while their rapid antigen test is negative.
  • This assumption was based on the data from PCR tests with nasopharyngeal swabs, which showed a lower viral load at an early stage of infection.
  • A longitudinal study from KU Leuven, UZ Leuven and imec revealed clear differences in the temporal dynamics of viral load for nasopharyngeal swab, saliva, breath, and antigen tests.

Agomab Expands Team with Reginald Brys as Head of Research and Maria Nichol as Head of IP

Retrieved on: 
Tuesday, December 21, 2021
Professional Services, Health, Legal, Research, Science, Pharmaceutical, Biotechnology, Doctor of Philosophy, Manifest and latent functions and dysfunctions, University, Natural science, Leadership, Therapy, Kidney, Representation before the European Patent Office, Acquisition, Head, KU Leuven, Mace Head Atmospheric Research Station, Drug development, Disease, Pharmacology, Patent, Biology, Fibrosis, Intellectual property, Pharmaceutical industry, Galápagos Islands, Research

Agomab Therapeutics NV (Agomab) today announced the expansion of its team with two key hires: Reginald Brys will join as Head of Research and Maria Nichol will become Head of Intellectual Property.

Key Points: 
  • Agomab Therapeutics NV (Agomab) today announced the expansion of its team with two key hires: Reginald Brys will join as Head of Research and Maria Nichol will become Head of Intellectual Property.
  • Onboarding Reginald and Maria is a good example of our progress to grow Agomab into a global leader, said Tim Knotnerus, Chief Executive Officer at Agomab Therapeutics.
  • Reginald has a long track record of success in leading research efforts that produce highly innovative drug candidates.
  • Reginald Brys will join Agomab from Galapagos NV, where he worked from 2000 in multiple leadership positions in the research organization.

Kraken Ventures Raises $65 Million for Early Stage Fund to Invest Across the Crypto & Fintech Ecosystem

Retrieved on: 
Friday, December 17, 2021
Finance, Banking, Professional Services, Technology, Software, GBP, Public policy, Harvard University, Ingmar De Poortere, Industry, CAD, AUD, Time, AI, City, LP, Decentralized finance, NYU, Â, Social impact, Investment, MBA, Engineering, Machine learning, Mavis, CHF, Head, JPY, Cryptocurrency, Financial services, Kraken, USD, EUR, KU Leuven, Kraken Ventures, Kraken: Anchor LP in Kraken Ventures, KRAKEN VENTURES, KRAKEN: ANCHOR LP IN KRAKEN VENTURES

Kraken Ventures, an independent investment fund led by Kraken alumni targeting early stage companies and protocols across the crypto and fintech ecosystem, has today announced the successful closing of its first fund, Kraken Ventures Fund I LP.

Key Points: 
  • Kraken Ventures, an independent investment fund led by Kraken alumni targeting early stage companies and protocols across the crypto and fintech ecosystem, has today announced the successful closing of its first fund, Kraken Ventures Fund I LP.
  • Were extremely pleased to have successfully closed our first fund, said Brandon Gath, Managing Partner of Kraken Ventures.
  • As part of Kraken Ventures global expansion, Kraken Ventures is pleased to announce the recent appointment of Laurens De Poorter as Head of Europe.
  • Kraken Ventures is an independent investment fund targeting early stage companies and protocols across the crypto and fintech ecosystem.

Hivebrite Sponsors Podcast Series to Help Alumni Advancement Professionals Make and Demonstrate a Greater Impact

Retrieved on: 
Tuesday, December 7, 2021
Research, University of Zurich, Knowledge, University of Amsterdam, American Heart Association, Somatosensory system, Imperial College London, Henley Business School, Stanford University, Corporation, Rotterdam School, Advancement, Organization, Partnership, Harvard Business School, Associate, Rotterdam School of Management, Erasmus University, Johns Hopkins University, Council, KU Leuven, Columbia Business School, Atlantic Film Festival, Alumnus, University, Support, Junior Achievement, Council for Advancement and Support of Education, Notre Dame, Video game, Management, Medicine, Industrial design

NEW YORK and PARIS, Dec. 7, 2021 /PRNewswire/ --Hivebrite, a community engagement platform , teamed up with alumni relations expert Sandra Rincn to create Brite Ideas , a podcast series to help advancement professionals make and demonstrate a more significant impact.

Key Points: 
  • NEW YORK and PARIS, Dec. 7, 2021 /PRNewswire/ --Hivebrite, a community engagement platform , teamed up with alumni relations expert Sandra Rincn to create Brite Ideas , a podcast series to help advancement professionals make and demonstrate a more significant impact.
  • Throughout the series, host Sandra Rincn and other advancement professionals discuss pressing issues, explore research findings from the field, and consider what alumni relations can learn from different industries.
  • Empowering alumni advancement professionals to meaningfully engage their alumni through intuitive technology has been a focus of Hivebrite since its creation.
  • Hivebrite also recently expanded its partnership with the Council for Advancement and Support of Education to better serve alumni advancement professionals.

DGAP-News: Atriva Therapeutics strengthens advisory board with Piet Wigerinck

Retrieved on: 
Thursday, December 2, 2021
Patient, Gesellschaft mit beschränkter Haftung, CEO, Orthohantavirus, Safety, CSO, Cell, Pharming, CMC, KU Leuven, Company, Viral load, MEK, Severe acute respiratory syndrome coronavirus 2, Gene expression, The Nomad Soul, Cytoplasm, COVID-19, History, Orthornavirae, Patent, RNP, RNA, Macrophage inflammatory protein, RSV, III, Therapy, Degenerative disease, Medicinal chemistry, Pharmaceutical industry, Vaccine, zapnometinib's mode of action with dual benefit, Atriva Therapeutics GmbH, ZAPNOMETINIB'S MODE OF ACTION WITH DUAL BENEFIT, ATRIVA THERAPEUTICS GMBH

Dr. Piet Wigerinck, former CSO of Galapagos, to strengthen Atriva's advisory board, bringing vast experience in late-stage pharmaceutical development

Key Points: 
  • Dr. Piet Wigerinck, former CSO of Galapagos, to strengthen Atriva's advisory board, bringing vast experience in late-stage pharmaceutical development
    Frans van Dalen, Pharm D., representative of Atriva's lead investor Meneldor, continues support for Atriva on the scientific board
    Tbingen and Frankfurt, Germany, December 02, 2021 - Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, today announced changes in its advisory board and its scientific board: Effective December 1, Piet Wigerinck, Ph.D., former Chief Scientific Officer (CSO) of the Belgian biotech company Galapagos, will join Atriva's advisory board on behalf of lead investor Meneldor.
  • D., founding partner and representative of Meneldor in Atriva's advisory board until now, will take a seat on the scientific board to continue his support for Atriva.
  • Paul Lelieveld, Ir., founding partner of Meneldor, said: "We warmly welcome Piet as a representative of Meneldor on the advisory board of Atriva.
  • Dr. Piet Wigerinck said: "I am very pleased to join the Atriva Therapeutics board at an exciting moment in its history.

Integra LifeSciences Announces Jan De Witte as President and Chief Executive Officer

Retrieved on: 
Thursday, October 28, 2021
Science, Procter & Gamble, RMD, McKinsey & Company, Integra, Technology, GE Healthcare, Merck KGaA v. Integra Lifesciences I, Ltd., Acceleration, Harvard University, UBM, COPD, Neurosurgery, Euronext, NASDAQ, TCC, NYSE, GE Global Research, Leadership, Heidrick & Struggles, ASX, CEO, Board, COVID-19, GE, News, Conditional sentence, Health, GLOBE, KU Leuven, ICP, Procter, Sleep apnea, Management

PRINCETON, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today announced that it has appointed Jan D. De Witte as its next President and Chief Executive Officer.

Key Points: 
  • PRINCETON, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today announced that it has appointed Jan D. De Witte as its next President and Chief Executive Officer.
  • Mr. De Witte succeeds Peter J. Arduini, who previously announced he will step down as Chief Executive Officer to accept the role of President and Chief Executive Officer of GE Healthcare.
  • With over two decades in the healthcare industry, De Witte brings global public company leadership experience as well as deep technological, operational and commercial expertise to Integra.
  • Mr. De Witte stated, I am honored and excited to be joining Integra and a very talented and dedicated team.

American Friends Of Capodimonte Museum In Naples, Italy Announce Post-Doctoral Curatorial Fellow Appointment

Retrieved on: 
Thursday, September 23, 2021
Singular, Authorship, Publication, Archaeology, Museum, Essay, Capodimonte, History of the University of Maryland, College Park, Cornell University, KU Leuven, Multimedia, AFC, University, Program, Sculpture, Friends, University College London, Female, Research, Department, College Park, University of Bologna, Museo di Capodimonte, Author, Leuven University Press

CHICAGO, Sept. 23, 2021 /PRNewswire/ -- American Friends of Capodimonte Museum (AFC) announces the appointment of Caroline Paganussi to the position of Post-Doctoral Curatorial Fellow.

Key Points: 
  • CHICAGO, Sept. 23, 2021 /PRNewswire/ -- American Friends of Capodimonte Museum (AFC) announces the appointment of Caroline Paganussi to the position of Post-Doctoral Curatorial Fellow.
  • She is the second Post-Doctoral Fellow and the fourth fellow to be installed by the AFC since the program started in 2017.
  • "We are looking forward to a close collaboration with our second Post-Doctoral American Friends of Capodimonte Fellow," said Director Sylvain Bellenger.
  • Paganussi's tenure at Capodimonte has also been generously supported by the Tecno Industrial Group and its founder, Capodimonte Advisory Board President Giovanni Lombardi.